Substrate utilization in sepsis and multiple organ failure

Détails

ID Serval
serval:BIB_AA31E719A615
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Substrate utilization in sepsis and multiple organ failure
Périodique
Critical Care Medicine
Auteur⸱e⸱s
Tappy  L., Chiolero  R.
ISSN
0090-3493 (Print)
Statut éditorial
Publié
Date de publication
09/2007
Volume
35
Numéro
9 Suppl
Pages
S531-4
Notes
Journal Article
Review --- Old month value: Sep
Résumé
Sepsis and multiple organ failure are characterized by an excessive release of inflammatory mediators and a marked stimulation of stress hormones. These in turn have profound effects on energy and substrate metabolism: energy expenditure is generally increased, and increased lipolysis and fat oxidation are observed. Net protein breakdown occurs and leads to accelerated wasting. Most of these effects can be produced in healthy humans by administration of bacterial endotoxin or by tumor necrosis factor-alpha. Hyperlactatemia is a hallmark of sepsis and critical illness, and its severity is related to mortality. An increased lactate production, possibly secondary to activation of Na-K adenosine 5'-triphosphatase and to muscle mitochondrial dysfunction, is involved. Lactate production by immune cells and wound tissue may also play a role. Long-chain, n-3 polyunsaturated fatty acids have anti-inflammatory effects that may be beneficial in sepsis. They also decrease the stimulation of stress hormones induced by bacterial endotoxin, possibly through an effect exerted at the level of the central nervous sytem. Their use in patients with sepsis does not lead to adverse metabolic effects.
Mots-clé
Critical Illness *Energy Metabolism Fatty Acids, Omega-3/pharmacology/therapeutic use Fish Oils/pharmacology/therapeutic use Humans Inflammation Mediators/metabolism Lactic Acid/metabolism Lipopolysaccharides/pharmacology Multiple Organ Failure/drug therapy/*metabolism Sepsis/drug therapy/*metabolism
Pubmed
Web of science
Création de la notice
24/01/2008 13:36
Dernière modification de la notice
20/08/2019 15:14
Données d'usage